Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SUPN stock price vs ON: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ON's multiple
Needs ON P/S.
Implied fair value · at SUPN's multiple
Needs SUPN P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SUPN FY 2025 (ended Dec 31, 2025) · ON FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Bear
$11.78
Base
$13.86
Bull
$15.94
ON SEMICONDUCTOR CORPORATION · implied price per share
Bear
$17.36
Base
$20.42
Bull
$23.49
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
0.00x
Net debt / EBITDA
Leverage against operating earnings
-6.69x
-2.97x
Cash and equivalents
Liquid reserves on the balance sheet
$496.66M
$2.55B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
SUPN vs JAZZ
INCYTE CORP
SUPN vs INCY
ANI PHARMACEUTICALS INC
SUPN vs ANIP
Vanda Pharmaceuticals Inc.
SUPN vs VNDA
Harmony Biosciences Holdings, Inc.
SUPN vs HRMY
Intel Corporation
SUPN vs INTC
NVIDIA Corporation
SUPN vs NVDA
Texas Instruments Incorporated
SUPN vs TXN
QUALCOMM INC/DE
SUPN vs QCOM
$23.23M
$900.00K
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SUPN can convert its 8.6% revenue growth and 89.6% gross margin into sustained operating profitability, then the stock may merit a buy because the current $48.05 price is well below the $74.45 ON-implied value; if not, the DCF range of $4.87 to $6.59 argues the market may still be overestimating intrinsic value.
SUPN’s current price of $48.05 sits below ON-implied value of $74.45, suggesting a large valuation gap on a P/S basis. However, ON comparison is complicated by very different business profiles, and the broader valuation signals are mixed given SUPN’s weak earnings base.
Supporting Metrics
Live quote
